Head-to-head
MOTS-c vs 5-Amino-1MQ
A field-by-field comparison of MOTS-c and 5-Amino-1MQ drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as metabolic compounds, so the useful question is how they differ within that category.
MOTS-c vs 5-Amino-1MQ at a glance
| Attribute | MOTS-c | 5-Amino-1MQ |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence grade | Emerging | Limited |
| Also known as | Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1-encoded peptide | 5-amino-1-methylquinolinium |
| Chain | 16 amino acid mitochondrial-derived peptide | Small molecule (not strictly a peptide) |
| Mechanism | Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress. | Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Blocking it raises intracellular NAD+ and SAM, increasing energy expenditure in fat cells. |
| Reported benefits | Improved insulin sensitivity and glucose disposal in rodent models · Enhanced fat oxidation and reduced fat accumulation · Exercise-mimetic effects on metabolism and physical capacity · Potential protection against diet-induced metabolic dysfunction | Reduced fat-cell size in rodent studies · Increased cellular NAD+ · Oral bioavailability — no injections |
| Reported side effects | Limited human safety data · Injection-site irritation · Possible hypoglycaemia in susceptible individuals | Insomnia if dosed late · Mild GI upset · Unknown long-term profile |
| Half-life | Estimated minutes to a few hours | Estimated several hours |
| Administration | Subcutaneous injection; oral capsules are marketed but less validated | Oral capsule |
| Dosing overview | Commonly cited at 5–10 mg daily, often for 4–12 week cycles | 50–150 mg once daily in the morning |
| Storage | Lyophilised powder refrigerated; reconstituted vials 2–8 °C and used within ~30 days | Cool, dry place away from light |
| Legal status | Research chemical; not approved as a drug. | Sold as a research compound; not an approved drug or dietary supplement. |
Key differences between MOTS-c and 5-Amino-1MQ
Both are metabolic compounds
MOTS-c and 5-Amino-1MQ are both indexed under metabolic, so they compete for the same use case rather than complementing each other. MOTS-c: "A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects." 5-Amino-1MQ: "An orally active NNMT inhibitor grouped with metabolic peptides, studied for fat-cell metabolism and NAD+ preservation."
Mechanism of action
MOTS-c: Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress. 5-Amino-1MQ: Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Blocking it raises intracellular NAD+ and SAM, increasing energy expenditure in fat cells.
Evidence quality is not equal
MOTS-c carries a Emerging evidence grade and 5-Amino-1MQ a Limited grade on this index. The grade describes the quality of published human data, not how well a compound works — MOTS-c has the better-documented record of the two, and claims made about 5-Amino-1MQ rest on thinner human evidence.
Half-life and dosing frequency
MOTS-c is listed at estimated minutes to a few hours; 5-Amino-1MQ at estimated several hours. That difference is what drives the reported schedules: Commonly cited at 5–10 mg daily, often for 4–12 week cycles versus 50–150 mg once daily in the morning
Route of administration
MOTS-c is administered by subcutaneous injection; oral capsules are marketed but less validated. 5-Amino-1MQ is administered by oral capsule.
Legal and regulatory status differs
MOTS-c: Research chemical; not approved as a drug. 5-Amino-1MQ: Sold as a research compound; not an approved drug or dietary supplement. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
MOTS-c is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c and used within ~30 days. 5-Amino-1MQ is stored cool, dry place away from light.
What MOTS-c and 5-Amino-1MQ have in common
- Category: both listed as Metabolic
Each compound in brief
MOTS-c
Metabolic · Emerging evidence
A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects.
Considerations: Most evidence is preclinical; human trials are small and early-phase · Short half-life may require daily or twice-daily dosing · Bioavailability of oral forms is uncertain compared with injection
5-Amino-1MQ
Metabolic · Limited evidence
An orally active NNMT inhibitor grouped with metabolic peptides, studied for fat-cell metabolism and NAD+ preservation.
Considerations: No published human trials · Often stacked with metabolic peptides · Marketed heavily ahead of the evidence
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.